Castration-Resistant Prostate Cancer (CRPC) or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report 2026

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size has grown strongly in recent years. It will grow from $8.43 billion in 2025 to $8.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to prostate cancer prevalence, hormone therapy resistance, oncology drug innovation, hospital-based cancer care, aging male population.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to biomarker-driven treatment, advanced targeted therapies, oral oncology adoption, oncology pipeline expansion, personalized cancer care. Major trends in the forecast period include rising use of androgen receptor inhibitors, growth of parp inhibitor therapies, expansion of combination treatment regimens, increased focus on precision oncology, shift toward oral oncology drugs.

The rising prevalence of prostate cancer is expected to drive the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is a malignancy that develops in the prostate gland, a small organ located below the bladder and in front of the rectum in men. The increasing prevalence of prostate cancer is largely due to an aging population, as the likelihood of developing the disease rises significantly with age. CRPC or HRPCA therapeutics play a key role in managing advanced prostate cancer that no longer responds to conventional hormone therapy. These treatments improve patient outcomes by slowing disease progression and managing symptoms, thereby enhancing quality of life. For instance, in October 2025, according to NHS Digital, a UK-based government agency responsible for healthcare statistics, there were 58,137 new diagnoses of prostate cancer in England in 2023, representing a 6% increase compared with 2022. Therefore, the rising prevalence of prostate cancer is fueling growth in the CRPC or HRPCA therapeutics market.

Major companies in the CRPC or HRPCA therapeutics market are focusing on developing innovative treatments and obtaining regulatory approvals, such as dual-action tablets, to enhance efficacy and patient outcomes. Dual-action tablets are advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways involved in CRPC treatment. For instance, in August 2023, Janssen Pharmaceuticals, a Belgium-based company, received U.S. FDA approval for Akeega, a novel tablet designed for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that combines a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When administered alongside prednisone, it significantly improves radiographic progression-free survival (rPFS) compared with conventional hormone therapy alone.

In June 2024, AstraZeneca plc, a US-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to advance cancer treatment by replacing traditional chemotherapy and radiotherapy with more targeted next-generation radioconjugate therapies. Fusion Pharmaceuticals Inc., a Canada-based biotech company, is actively developing FPI-2265, a targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased production costs in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market by raising prices of oncology APIs, biologics, and advanced drug delivery components. Targeted therapies, PARP inhibitors, and immunotherapies are most affected, particularly in North America and Europe. Oncology centers experience higher treatment costs. However, tariffs are encouraging domestic manufacturing of cancer therapeutics, supporting long-term drug availability.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market research report is one of a series of new reports that provides castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market statistics, including castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics industry global market size, regional shares, competitors with a castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market share, detailed castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics industry. This castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Castration-resistant prostate cancer (CRPC), also known as hormone-refractory prostate cancer (HRPCA), refers to advanced prostate cancer that continues to progress despite reduced testosterone levels, typically following androgen deprivation therapy. Therapeutics for CRPC aim to overcome resistance mechanisms, improve patient outcomes, and extend survival.

The main therapy types for CRPC or HRPCA include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Hormonal therapy involves using hormones or hormone-blocking drugs to slow or stop the growth of hormone-sensitive cancers. These treatments are administered orally, by injection, or intravenously and serve a range of end-users, including hospitals, oncology centers, ambulatory surgical centers, and others.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market consists of sales of enzalutamide, darolutamide, abiraterone, and cabazitaxel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.